FDA Approves First Oral Targeted Therapy for Rare Muscle and Skin Disease Dermatomyositis

For the estimated 1 in 100,000 people who develop dermatomyositis each year, treatment has historically meant a difficult trade-off: manage the debilitating muscle weakness and painful skin rashes, but endure the heavy toll of chronic, high-dose steroids. That paradigm shifted on Thursday when the FDA approved Lisraya (brepocitinib), the first oral targeted therapy specifically indicated for the rare autoimmune disease.[1][2]

Dermatomyositis occurs when the immune system mistakenly attacks the body's own muscles and skin. This rogue immune response leads to profound physical disability, disfiguring cutaneous lesions, and a loss of independence that affects nearly every aspect of a patient's daily life. Until now, patients have lacked a therapy designed specifically for their condition's underlying biology.[1][5]

Lisraya, developed by Priovant Therapeutics and Roivant, is a first-in-class dual inhibitor of the TYK2 and JAK1 signaling pathways. By blocking these specific immune channels, the once-daily tablet disrupts the inflammatory response at its source rather than broadly suppressing the entire immune system. This targeted approach represents a fundamental shift in how the disease is managed clinically.[4][6]

The FDA's decision was anchored by the Phase 3 VALOR trial, described by researchers as the largest study ever conducted for the condition. The trial tracked 241 adults across 90 sites globally over a 52-week period. Patients receiving a 30-milligram daily dose of Lisraya were more than four times as likely to report overall disease improvement compared to those on a placebo.[3][4]

Beyond clinical scores, the trial measured tangible quality-of-life improvements. Patients on the targeted therapy achieved clinically meaningful gains in everyday functions that the disease typically steals. Participants reported significant improvements in their ability to manage pain, get dressed independently, climb stairs, and run errands.[3]

Crucially, the trial demonstrated that Lisraya could free patients from long-term steroid reliance, which carries severe cumulative toxicities. Among participants taking oral corticosteroids at the start of the study, nearly 42% of those treated with Lisraya discontinued steroids completely by the end of the year, compared to just 23% in the placebo group.[3]

"For many decades, the treatment of dermatomyositis has relied on chronic steroids, non-specific immunomodulators, and intravenous immunoglobulin—therapies not targeted to the underlying disease pathobiology," said Dr. Ruth Ann Vleugels of Mass General Brigham and Harvard Medical School. She noted the approval marks a turning point, offering a targeted medicine that delivers meaningful benefits across muscle and skin activity while reducing steroid dependence.[1][3]

Because Lisraya belongs to the broader class of JAK inhibitors, it carries a standard boxed warning regarding the risk of serious infections, major adverse cardiovascular events, and thrombosis. However, the FDA granted the drug a broad label, meaning it is approved for use in all adults with dermatomyositis regardless of their prior treatments or specific clinical presentation.[2][5]

The drug is immediately available in the United States, and an ongoing open-label extension of the VALOR trial will continue to track patients to provide longer-term data on the therapy's durability. For patients who have exhausted conventional options, the arrival of a mechanism-guided oral treatment represents a major step forward in reclaiming their quality of life.[2][3]